GLP-1

News

Lilly unveils employer scheme for weight-loss drug Zepbound

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

News

Can GLP-1 drugs help tackle addiction?

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

News

Novo Nordisk plans €432m investment in Irish GLP-1 plant

Novo Nordisk invests in an Irish plant as it prepares for regulatory approvals of its Wegovy pill outside the US.

News

Head to head figurine fights, red and blue

Lilly says orforglipron tops Novo pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

Lilly unveils employer scheme for weight-loss drug Zepbound

Can GLP-1 drugs help tackle addiction?

FDA ramps up its pushback against compounded GLP-1s

Novo Nordisk plans €432m investment in Irish GLP-1 plant

Lilly says orforglipron tops Novo pill in diabetes trial

Novo Nordisk to cut GLP-1 prices in tough US market

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

GLP-1

Editor's Picks